title: Steroid avoidance in two-haplotype-matched living donor renal transplants with basiliximab induction therapy.
abstract: BACKGROUND
  Induction therapy and haplotype matching are utilized to mitigate immunologic risk in renal transplantation. The incidence of acute rejection (AR) of renal allografts has been reported to be as low as 9.3% within the first year among two-haplotype-matched siblings with no induction and triple-drug maintenance immunosuppression. We report our use of basiliximab induction in a series of two-haplotype-matched living donor renal transplants (LDRT).
  
  
  METHODS
  We retrospectively reviewed 25 patients who received a two-haplotype-matched LDRT with basiliximab induction therapy. The primary endpoints were acute rejection (AR) episodes at 6 and 12 months and 1-year patient and graft survival rates. The secondary endpoints were the incidence of delayed graft function (DGF), cytomegalovirus (CMV), and BK virus (BKV).
  
  
  RESULTS
  The rate of AR at 6 months was 0% (0/25) and 4% (1/25) at 12 months. The 1-year graft and patient survival rates were 100%. The incidence of DGF was 4% (1/25), while the incidences of CMV and BKV were 0%.
  
  
  CONCLUSIONS
  Basiliximab induction therapy with a steroid-sparing regimen yields favorable results in two-haplotype-matched LDRT, including a notable reduction in the rates of AR as compared to triple-drug maintenance immunosuppression without induction. These patients have excellent graft survival with no increased incidences of secondary infections.
authors.affiliation: Department of Surgery, Weill Cornell Medical Center, New York, NY 10068, USA. cafaneh@gmail.com
authors.forename: C
authors.initials: C
authors.lastname: Afaneh
authors.forename: J
authors.initials: J
authors.lastname: Halpern
authors.forename: E
authors.initials: E
authors.lastname: Cheng
authors.forename: M
authors.initials: M
authors.lastname: Aull
authors.forename: J
authors.initials: J
authors.lastname: Figueiro
authors.forename: S
authors.initials: S
authors.lastname: Kapur
authors.forename: D B
authors.initials: DB
authors.lastname: Leeser
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001739:BK Virus / Q000302:isolation & purification; D000077552:Basiliximab; D003587:Cytomegalovirus / Q000302:isolation & purification; D005260:Female; D006085:Graft Survival; D006239:Haplotypes; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D016030:Kidney Transplantation; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab